Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure. The firm's products include GastroPlus that simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs administered to humans and animals; DDDPlus, which simulates in vitro laboratory experiments to measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus that simulates laboratory experiments. The company also offers ADMET Predictor, a computer program that takes molecular structures as inputs and predicts their properties; MedChem Studio, a tool for data mining and designing new molecules; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it is involved in the analysis and reporting of data collected during clinical trials of new and existing pharmaceutical products; and provision of consulting and contract research services to the pharmaceutical industry. The company operates in North America, South America, Europe, Japan, Australia, New Zealand, India, Singapore, and the Peoples Republic of China. Originally SBIR involved in 2007, firm re-entered the arena in 2021 - both projects continuing into Phase II
